30 ft Robot In Wimpole Street To Power Pioneer e-Prescription Pharmacy Expansion

Pharmacierge, the leader in private e-prescription app and delivery services announces its forthcoming expansion within the heart of London’s healthcare district.  The expansion includes an extensive new 5,500 sqft dispensary equipped with a 30ft dispensing robot, both the largest of their kind in the prestigious Harley Street Medical Area (HSMA).  Pharmacierge is itself backed by 80 leading private GPs and Consultants spanning all medical specialties.

Acquiring the additional lease in Wimpole Street marks a significant milestone on Pharmacierge’s mission to becoming the pharmacy partner of choice to all leading private practices and private hospitals. With this move, the brand’s operations parallel to Harley Street will grow to 8,000 sqft, or tenfold the size of its original location in 2015.

Cutting-Edge Software And Pharmacy Design

In its relentless pursuit of innovation, Pharmacierge has engaged a world-renowned pharmacy designer to reimagine its latest incarnation.  The ambitious transformation of two 18th-century Georgian properties into one streamlined clinical space is already underway.  The project aspires to revolutionising the private pharmacy pathway, marrying cutting-edge technology and robotics with traditional pharmacy values and integrity.  In addition to generic and branded medicines, the plans also include dedicated sub-divided areas for controlled, refrigerated and biological medications.

Robotic Dispensing and AI-Driven Stock Management

A 30 ft multi-arm dispensing robot, unprecedented in central London, will soon occupy one wing of the new premises, with medication chutes spiralling down through the floor to the spacious modern dispensary beneath.  This robotic automation is projected to improve overall efficiency and enhance rapid availability of the broadest possible pharmacy formulary.  Pharmacierge already caters to a network of over 4,500 GP and Consultant users.

Scalable Partnerships with Private Practices and Hospitals

Pharmacierge is already the preferred pharmacy partner to many of the leading UK and US hospital groups in London.  With these robotic automation and scalability gains, it plans to bring the time and cost-saving benefits of ‘ePrescribing-as-a-service’ to further private practitioners, hospitals and private patient units (PPU) throughout the UK.  Over 90% of clinicians surveyed believe that Pharmacierge ePrescribing saves their practice 5-15 mins per prescription, while patients are spared the impact and inconvenience of multiple car journeys and pharmacy visits.  Institutional benefits include centralised administration, real-time tracking and simplified pre-op medication pathways.

Pharmacy and Medical Heritage

Pharmacierge’s co-founders share well over a century of combined medical and pharmacy heritage in the Harley Street area, having previously co-founded The Doctor’s Laboratory (TDL), also on Wimpole Street, and other pharmacies within the Marylebone and Mayfair estates.

Commenting on the transaction, Edward Ungar, CEO said, “While our mPrescribe® technology now equally serves clinicians and patients outside of London, we felt very strongly that only a local investment would remain faithful to our brand values, our roots and the private medical community who have supported us through thick and thin.”

Julian Best, Executive Property Director of The Howard de Walden Estate comments: “We are delighted Pharmacierge has chosen to expand their operation in the Harley Street Medical Area, bolstering the technology led patient experience for the delivery of prescriptions and ensuring the area continues to offer the highest level of patient service.”


Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy